Update on the strategic development of the study drug Remygen®

Diamyd Medical has filed a preliminary patent application on the formulation and release characteristics of the GABA-based study drug Remygen®. Based on the feedback from a scientific meeting yesterday with the Swedish Medical Products Agency, and in collaboration with Diamyd Medical’s scientific network, the Company will now commence designing the first clinical trial based on Remygen® and defining the long-term drug development strategy.“The development of Remygen® marks a significant milestone for Diamyd Medical,“ says Ulf Hannelius, CEO of Diamyd Medical. “We can now see the results of